We previously generated transgenic mice expressing human apolipoprotein (apo-) B and demonstrated that the plasma of chow-fed transgenic animals contained markedly increased amounts of LDL (Linton, M. F., R. V. Farese, Jr., G. Chiesa, D. S. Grass, P. Chin, R. E. Hammer, H. H. Hobbs, and S. G. Young 1992. J. Clin. . In this study, we fed groups of transgenic and nontransgenic mice either a chow diet or a diet high in fat (16%) and cholesterol (1.25%). Lipid and lipoprotein levels were assessed, and after 18 wk of diet, the extent of aortic atherosclerotic lesions in each group of animals was quantified. Compared with the female transgenic mice on the chow diet, female transgenic mice on the high-fat diet had higher plasma levels of cholesterol (312±17 vs 144±7 mg/dl; P < 0.0001) and human apo-B (120±8 vs 84±3 mg/dl; P < 0.0001). The higher human apo-B levels were due to increased plasma levels of human apo-B48; the human apo-B100 levels did not differ in animals on the two diets. In mice on the high-fat diet, most of the human apo-B48 and apo-B100 was found in LDL-sized particles. Compared with nontransgenic mice on the high-fat diet, the transgenic animals on the high-fat diet had significantly increased levels of total cholesterol (312±17 vs 230±19 mg/dl; P < 0.0001) and non-HDL cholesterol (283±17 vs 193±+19 mg/dl; P < 0.0001). The extent of atherosclerotic lesion development within the ascending aorta was quantified by measuring total lesion area in 60 progressive sections, using computerassisted image analysis. Neither the chow-fed transgenic mice nor the chow-fed nontransgenic mice had significant atherosclerotic lesions. Nontransgenic animals on the highfat diet had relatively small atherosclerotic lesions ( < 15,000 imm2/section), almost all of which were confined to the proximal 400 ,im of the aorta near the aortic valve. In contrast, transgenic animals on the high-fat diet had extensive athero- Thus, human apo-B expression, in the setting of a diet rich in fats, causes severe atherosclerosis in mice. (J. Clin. Invest. 1995Invest. . 95:2246Invest. -2257
Introduction
Considerable evidence indicates that the apo-B-containing lipoproteins (e.g., VLDL, intermediate density lipoproteins [IDL] ,' LDL, lipoprotein [a] ) are atherogenic (1) . Feeding a diet rich in fats and cholesterol to nonhuman primates (2, 3) as well as certain strains of mice (4, 5) results in elevated levels of the apo-B-containing lipoproteins, and is accompanied by the development of atherosclerotic lesions in the large arteries. Moreover, human lipoprotein disorders associated with retarded clearance of the apo-B-containing lipoproteins (type III hyperlipoproteinemia [6] , familial defective apolipoprotein B100 [7] , and familial hypercholesterolemia [8] ) are characterized by elevated levels of the apo-B-containing lipoproteins and premature atherosclerotic disease. In recent years, several groups have used homologous recombination in mouse embryonic stem cells to generate apo-E-deficient mice (9, 10) and LDL receptor-deficient mice (11) . Both of these targeted mutations interfere with the clearance of apo-B-containing lipoproteins from the plasma; in both of these animal models, the plasma levels of the apo-B-containing lipoproteins are elevated and there is increased susceptibility to the development of atherosclerosis (12) (13) (14) (15) .
To study the metabolic and pathologic consequences of an increased rate of production of the apo-B-containing lipoproteins, we recently generated transgenic mice expressing high levels of human apo-B (16) . The mice were generated using a 79.5-kb genomic DNA fragment spanning the entire human apo-B gene; interestingly, the human apo-B transgene was expressed at high levels in the liver, but not in the intestine (16, 17) . On a chow diet, the human apo-B100 levels in the plasma of hemizygous transgenic animals were 50-60 mg/dl, nearly equivalent to the levels in normolipidemic humans. The distribution of human apo-B100 in the plasma lipoproteins of the chow-fed transgenic mice was virtually identical to the distribution of apo-B 100 in human plasma, with > 90% of the human apo-B 100 in the LDL and the remainder in the VLDL and IDL. Because the human apo-B-containing lipoproteins in the transgenic mouse plasma were enriched in both cholesterol and triglycerides, the transgenic animals had significantly elevated plasma levels of both cholesterol and triglycerides (16) .
In the human apo-B transgenic mice, the high levels of LDL in chow-fed hemizygous mice were obviously due, at least in part, to the overproduction of apo-B in the liver ( 16) . In considering how the human apo-B mice might respond to a diet rich in fats and cholesterol, we found it difficult to make a priori predictions. The fact that the transgenic animals already had relatively high levels of human apo-B on a chow diet suggested that they might develop very high levels of apo-B in the setting of a high-fat diet. Marked elevations in apo-B levels are observed in other mammals when they are placed on a high-fat diet (2) . On the other hand, it seemed possible that having a full complement of apo-E in the plasma, as well as LDL receptors in the liver, might prevent a large increase in apo-B and cholesterol levels. Similarly, one could imagine that the high levels of apo-B mRNA editing activity in the mouse liver, which is responsible for the production of apo-B48-containing lipoproteins, might serve to protect mice from severe hypercholesterolemia (18) . We also found it difficult to make specific predictions about the susceptibility of the human apo-B transgenic mice to aortic atherosclerosis. Because LDL is considered atherogenic, it seemed possible that the relatively high levels of LDL cholesterol in the chow-fed animals would render them susceptible to atherosclerosis. Alternatively, it would be reasonable to postulate that the development of atherosclerosis in these animals might require a high-fat diet, which, at least in the C57BL/6 strain, is accompanied by a decrease in HDL cholesterol levels (19) (20) (21) and an induction of a variety of inflammatory genes (22) . In this paper, we report studies that address these important issues. We have thoroughly characterized the response of the human apo-B transgenic animals to a diet rich in fats and cholesterol, and we quantify the extent of aortic atherosclerosis in groups of transgenic and nontransgenic mice fed either chow or high-fat diets.
Methods
Animals and diets. C57BL/6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME). The human apo-B transgenic founder animal 1102 (a C57BL/6 x SJL F2 animal) (16) was backcrossed with a C57BL/6 male animal; the first litter yielded three male transgenic animals. These three males were backcrossed with C57BL/6 females to produce all of the human apo-B transgenic animals used in this study. All of the transgenic animals were hemizygous for the transgene. The nontransgenic controls in these studies were littermates of the transgenic animals. Thus, the genomes of both the transgenic and the nontransgenic animals were 87.5% identical to that of C57BL/6 mice.
All mice were weaned at 21 d and housed in a full barrier transgenic facility on a 12-h light-dark cycle, with free access to food and water.
Blood samples were collected from the retrooribital sinus (at 5 wk of age) in serum separator tubes containing EDTA, and plasma was obtained by centrifugation. Transgenic animals were identified by a monoclonal antibody-based sandwich RIA for human apo-B100 (16) . A total of 24 female transgenic mice, 6 male transgenic mice, 24 female nontransgenic mice, and 6 male nontransgenic mice were placed on a high-fat diet between 5 and 8 wk of age; an identical number of transgenic and nontransgenic animals were continued on a chow diet (Breeder Chow; Ralston Purina Co., St. Louis, MO). The synthetic high-fat diet (purchased from ICN Biomedicals, Inc., Aurora, OH) contained 15% cocoa butter, 1% corn oil, 50% sucrose, 20% casein, 1 Antibodies and immunoassays. Measurement of total human apo-B levels (apo-B100 and apo-B48) and human apo-B100 levels were performed on all of the male and female transgenic mice. Quantitation of human apo-B100 in transgenic plasma was performed using a solidphase competitive RIA (16) 25 JAI of a fixed concentration of '"I-labeled human LDL (350,000 cpm/well) was added to each well. The human LDL was prepared from human plasma by ultracentrifugation and radioiodinated by the lactoperoxidase method to a sp act of 5,000-10,000 cpm/ng. The plates were incubated at 40C overnight and washed six times with SPRIA; each well was then counted in a gamma counter. The standard curve for the assay was constructed from dilutions of a human plasma sample that had an apo-B concentration of 60 mg/dl. The concentration of human apo-B in the transgenic plasma samples was determined by a standard curve and a linear regression of logit B/Bo vs the log of the standard concentration, where B and Bo are the specific counts bound in the presence and absence of competitor, respectively. The total human apo-B level (human apo-B100 and human apo-B48) was measured using a competitive RIA that was identical to this assay except that the 96-well plates were initially coated with PBS containing 2 ug/ml of mAb lDl, which binds to both apo-B48 and apo-B100 (26) (near apo-B amino acid 500). Antibody ID1 does not bind to mouse apo-B. Mouse apo-B plasma concentrations were measured on seven female mice in each group using a rocket immunoassay that was established in the laboratory of Dr. George Melchior (The Upjohn Co., Kalamazoo, MI) (23) . The rabbit anti-mouse apo-B antibody used in the rocket immunoassay did not detect human apo-B.
Apo-B mRNA editing. To analyze the extent of editing of the human apo-B mRNA and the mouse apo-B mRNA, we prepared cDNA from the kidney, intestine, and liver of transgenic and nontransgenic animals. Animals were killed either after a 14-h fast or within 1 h of the removal of food from their cages. Mouse organs were harvested directly into liquid nitrogen, and total cellular RNA was prepared using the Totally RNA purification kit (Stratagene Inc., La Jolla, CA). To prepare cDNA for the primer extension assays, 5-10 jig of the total RNA was first treated with 0.5 ,ul of DNase I (RNase-free, from Boehringer Mannheim Biochemicals) for 10 min at 37°C. The reaction was terminated by incubation at 90°C for 10 min. The DNase I pretreatment of the RNA was invariably successful in eliminating genomic DNA contamination of the RNA; with the DNase-treated RNA as a substrate, it was impossible to enzymatically amplify short segments of the apo-B cDNA or gene using Thermus aquaticus (Taq) polymerase. After pretreatment of the RNA with DNase I, cDNA was synthesized from 5-10 l.g of RNA using a mouse and human apo-B-specific oligonucleotide (5' CCACAT-T1TGAATCCAAGATGCAGTACTACT 3', corresponding to human apo-B cDNA nucleotides 6885-6855) (27) , and 1 01 of StrataScript RNase H -reverse transcriptase, according to the instructions provided in the Stratascript RT-PCR kit (Stratagene). Short (278-bp) segments of mouse and human apo-B cDNA were amplified from the singlestranded cDNA using Taq polymerase (Boehringer Mannheim Biochemicals) and the same species-specific apo-B oligonucleotide primers that we described previously (27) . To measure the extent of apo-B editing, the amplified segments of mouse apo-B cDNA and human apo-B cDNA were analyzed using a primer extension assay (28) .
Preparation of aortic sections. In this study, we performed comprehensive atherosclerosis quantification studies on the first 12 female mice of each group that completed 18 wk of diet. Atherosclerosis quantification studies were performed on five of the six male mice (One male in each group died before the end of the 18-wk diet period.). Mice were anesthetized with Metofane (methoxyflurane); (Pitman-Moore, Inc., Mundelein, IL). Hearts were exposed by thoracotomy; after nicking of the inferior vena cava, the animals were perfused via ventricular puncture, first with PBS to flush out the blood, and then with 10% neutral buffered formalin for 5 min to fix the aorta. The hearts (and the thoracic aorta) were dissected away from the thorax and stored in 10% formalin at 40C before sectioning. The 
Results
Apolipoprotein B levels and distribution. In female human apo-B transgenic mice on a chow diet, the mean level of total human apo-B (measured with an RIA that detects both human apo-B100 and human apo-B48) was 83.7 mg/dl, whereas the mean human apo-B100 level in the same animals was 62.9 mg/dl (Table I) . In female transgenic animals on a high-fat diet, the total apo-B levels increased -44%, to 120.2 mg/dl, but the human apo-B 100 levels in these mice were no higher than those in the chow-fed mice. The findings in the male transgenic mice were similar: the total human apo-B levels increased on the high-fat diet, whereas the apo-B100 levels remained unchanged. Male transgenic mice did, however, have 52% lower total human apo-B levels (P < 0.0001) and 42% lower human apo-B100 levels than the female mice (P < 0.0001) ( Table I ).
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The finding that total apo-B levels increased in response to a high-fat diet while apo-B 100 levels were unchanged implied that the high-fat diet may have resulted in increased plasma levels of human apo-B48. To test this possibility, we obtained plasma samples after a 14-h fast, fractionated the plasma samples on a Superose 6/60 column, and then performed Western blot analysis of the fractions, using the human apo-B-specific mAb, C1.4. These studies confirmed our suspicion that the highfat diet resulted in markedly increased levels of human apo-B48 (Fig. 1 A) . These chromatographic studies also permitted us to compare the distribution of human apo-B100 and apo-B48 on the two diets. In the chow-fed transgenic mice, virtually all of the human apo-B 100 was in the LDL fraction; the human apo-B48 was more widely distributed, but most was in LDLsized particles. On the high-fat diet, most of the human apo-B100 was again found in the LDL-sized particles. The apo-B100 in the plasma of animals on the high-fat diet was, however, found in slightly larger particles than in the chow-fed animals. Interestingly, the vast majority of the human apo-B48 was also in LDL-sized particles, with only small amounts of apo-B48 in the VLDL and IDL. To ensure that this finding was not a peculiarity of human apo-B48, we performed Western blots with a rabbit antibody specific for mouse apo-B. In the transgenic animals fed either the chow diet or the high-fat diet, there were no differences in the distributions of the mouse and human apo-B proteins (Fig. 1, A and B) . In the nontransgenic animals, we also found that most of the mouse apo-B48 was in LDL-sized particles (data not shown).
The human apo-B mRNA is known to be edited by the mouse apo-B mRNA editing machinery (27) . We wanted to determine whether the high levels of human apo-B mRNA in the liver of the transgenic animals would overwhelm this machinery. If the human apo-B mRNA saturated the apo-B editing machinery, one might expect to find decreased editing of the mouse apo-B mRNA in the transgenic animals compared with the nontransgenic mice. This was not the case: the amount of editing of the mouse apo-B mRNA in the liver was virtually identical in the transgenic and nontransgenic animals, regardless of whether the animals were fed the chow or the high-fat diet (Table II) . We were unable to detect an effect of the high-fat diet on the extent of apo-B mRNA editing; neither could we detect different extents of editing in animals that had been fasted for 14 h before death compared with animals that had been fasted for only 1 h before death.
For seven animals in each of the four groups of mice, we measured mouse apo-B levels, using a rocket immunoassay that was specific for mouse apo-B. The mouse apo-B levels in both the chow-fed transgenic and nontransgenic mice were 10-15 mg/dl; on a high-fat diet, the mouse apo-B levels approximately doubled in both transgenic and nontransgenic mice.
Lipid levels and lipid distribution. In this study, we measured lipid and lipoprotein levels in 24 transgenic females, 6 transgenic males, 24 nontransgenic females, and 6 nontransgenic males, on both the chow diet and the high-fat diet. Table I shows the lipid and lipoprotein levels in the transgenic and nontransgenic mice on the two diets, and provides statistical comparisons between the levels in male and female mice. Fig.  2 illustrates the differences in lipid and lipoprotein levels in the female transgenic and nontransgenic mice, and provides statistical comparisons between the levels observed. In considering the large amount of data presented in Table I and Fig. 2 , several findings should be underscored. First, we found that the total and non-HDL cholesterol levels were significantly higher in the transgenic animals than in the nontransgenic animals, on both the chow diet and the high-fat diet. For example, in female transgenic animals on the high-fat diet, the mean total cholesterol level was 312 mg/dl, compared with 230 mg/dl in the nontransgenic animals (P = 0.0025). Second, in response to the high-fat diet, the total and non-HDL cholesterol levels increased more in the female transgenic animals than in the female nontransgenic animals. For example, on the high-fat diet, the mean Figure 1 . Western blot demonstrating the distribution of human and mouse apo-B48 and apo-B100 in the plasma of the human apo-B transgenic mice. Plasma was pooled from six mice that had been on either the chow or the high-fat diet for 5 wk; 120 1A of the pooled plasma sample was subjected to size-fractionation on a Superose 6 column. Consecutive fractions were combined and electrophoresed on 3-12% gradient SDS-polyacrylamide gels; western blots were then performed using a human apo-B-specific monoclonal antibody, CI.4 (A), or a rabbit antibody to mouse apo-B (B). On two occasions, we performed an identical Western blot analysis to assess the distribution of apo-E in the transgenic and nontransgenic mice on the high-fat diet, using a rabbit antiserum to rat apo-E (kindly provided by K. Weisgraber at the Gladstone Institute of Cardiovascular Disease). For both transgenic and nontransgenic mice, most (> 85%) of the apo-E was in fractions 17-24. The transgenic mice had slightly lower amounts of apo-E in fractions 31-36, compared to the nontransgenic mice.
non-HDL cholesterol level in the transgenic mice was 91 mg/ dl higher than that of the nontransgenic mice; on the chow diet, it was only 49 mg/dl higher than in the nontransgenic mice. Third, the HDL cholesterol levels in the female transgenic mice were slightly but significantly lower (by 8 mg/dl) compared with the female nontransgenic mice. The lower HDL cholesterol levels in the transgenic mice were observed on both diets. Fourth, on either diet, the male transgenic and nontransgenic animals had higher HDL cholesterol levels than the female animals. Fifth, the triglyceride levels were higher in the transgenic mice than in the nontransgenic mice, but only on the chow diet. On the high-fat diet, the triglyceride levels were low and there were no differences between the transgenic and nontransgenic mice. The low triglyceride levels on the high-fat The percent editing of the human and mouse apo-B mRNA were performed as previously described (27) . The values shown represent the mean±SEM for three mice in each group. ND, not determined because the human apo-B transgene is not expressed in the mouse intestine; NA, not applicable. diet is characteristic of the synthetic high-fat diet that was used in this study (30, 31) .
To determine the distribution of cholesterol within the plasma lipoproteins, plasma samples were fractionated by Superose 6 chromatography. Consistent with our earlier studies on the distribution of cholesterol in the human apo-B transgenic founders ( 16), we found that the female transgenic mice on the chow diet had a marked increase in LDL cholesterol compared with the nontransgenic animals (Fig. 3) . The amount of LDL cholesterol in the plasma of the transgenic mice on the highfat diet was much higher than in the nontransgenic mice; it was also higher than the amount of LDL cholesterol in the plasma of transgenic mice on the chow diet (Fig. 3) . The chromatography studies confirmed the decrease in HDL cholesterol levels in the transgenic animals. The increase in VLDL cholesterol in the transgenic mice on the high-fat diet was similar to that observed in the nontransgenic mice. Consistent with these findings, we observed increased amounts of the pre-fl-migrating lipoproteins 2250 Purcell-Huynh et al. on the high-fat diet in both transgenic and nontransgenic animals (Fig. 4) .
Superose 6 cholesterol distribution profiles were also performed on male transgenic and nontransgenic mice. In keeping with the lower human apo-B levels in male transgenic mice, we found that the male mice had 20-30% lower LDL cholesterol peaks than the females, on both the chow and the highfat diets (data not shown).
Quantification ofatherosclerosis in the proximal ascending aorta. To assess the degree of atherosclerosis in the transgenic and nontransgenic mice, we used a computer-assisted image analysis system to quantify the atherosclerotic lesions within each of 60 progressive sections spanning the proximal 1, 200 ,um of the ascending aorta. On a chow diet, neither the transgenic nor the nontransgenic mice had significant atherosclerotic lesions. In these animals, the mean lesion area was < 200 giM2 per section. On the high-fat diet, the nontransgenic females had small atherosclerotic lesions, and most of these were confined to the proximal 400 glm of the aorta (Fig. 5 A) . Fraction Number Figure 3 . Distribution of cholesterol in the plasma of female human apo-B transgenic mice and nontransgenic mice, as assessed by Superose 6 chromatography, on a chow diet (top) and a high-fat diet (bottom). aorta ( Fig. 5 A) . The mean lesion area per section in the female transgenic mice was 163,158±3,489 yim2, whereas it was 14,580±1,179 Lm2 in the female nontransgenic mice (P < 0.0001). The atherosclerotic lesions in the male mice were smaller than those in females, but the male transgenic mice still had larger lesion areas than the male nontransgenic mice (45,522±8,877 Am2 vs 8,191±681 gM2; P < 0.05) (Fig. 5 B) .
* pre y -origin Section Number Fig. 6 shows typical Oil Red O-stained sections from the female nontransgenic mice (Fig. 6 , A and C) and female transgenic mice (Fig. 6, B and D (Fig. 7 B) . Fig. 8 is a photomicrograph of a lesion from one of the transgenic animals, showing foam cells and abundant cholesterol crystals. The electron micrograph in Fig. 9 , in addition to showing foam cells and cholesterol crystals at higher resolution, clearly reveals the endothelial cells. 
Discussion
In this study, we characterized the plasma lipid, apo-B, and lipoprotein levels in human apo-B transgenic mice on chow and high-fat diets and examined the susceptibility of these mice to aortic atherosclerotic lesions. The genetic background of the mice was predominantly C57BL/6, a strain that has been shown to be susceptible to aortic atherosclerosis in response to a highfat diet (5, 32) . The line of transgenic mice used in this study expressed high levels of human apo-B; chow-fed transgenic animals had human apo-B100 plasma levels that were nearly as high as those in normolipidemic humans and had substantially increased amounts of LDL cholesterol in the plasma. throughout the proximal 1,200 Jsm of the ascending aorta and were frequently circumferential. In contrast, the lesions in the female nontransgenic mice fed the high-fat diet were small and largely confined to the aortic sinuses near the aortic valve. The virtual absence of atherosclerotic lesions in the apo-B transgenic animals on the chow diet contrasts with the relatively severe lesions observed in apo-E-deficient mice on a chow diet (10, 12, 14, 15) . The susceptibility of chow-fed apo-E-deficient mice to atherosclerosis may relate to their much higher total plasma cholesterol levels (400-600 mg/dl), the marked accumulation of VLDL-IDL cholesterol in their plasma, or the fact that those mice have marked reductions in HDL cholesterol levels (12, 33) . The virtual absence of atherosclerosis in the chow-fed human apo-B transgenic mice is, however, consistent with the pathologic studies of LDL receptor-deficient mice (13) , which, on a chow diet, have total plasma cholesterol levels of -250 mg/dl and relatively normal HDL cholesterol levels. After 12 mo on a chow diet, the LDL receptor-deficient mice had only small accumulations of foam cells within the aortic sinuses (13) . Several factors might be important in explaining the absence of atherosclerotic lesions in the chow-fed human apo-B transgenic mice. High-fat diets are known to induce various inflammatory genes, and this induction may be important in atherogenesis (22) . On a chow diet, in the absence of the induction of inflammatory genes, it is possible that the total cholesterol levels observed in the apo-B transgenic mice (-150 mg/dl) are simply not high enough to initiate atherosclerosis, at least in an 18-wk time frame. In addition, it is possible that the relatively normal HDL cholesterol levels in the chow-fed apo-B transgenic mice may serve to protect these animals from atherosclerosis. To address this issue, we have recently generated mice that express both human apo-B and human cholesteryl ester transfer protein (34); these mice do not have increased total cholesterol levels but show a striking reduction in HDL cholesterol levels and an LDL cholesterol:HDL cholesterol ratio of -2:1. If our future studies reveal that these mice develop atherosclerosis on a chow diet, it will add to the accumulating data (33, 35) that HDL play an important role in preventing murine atherosclerosis.
On a high-fat diet, the mean total cholesterol level in the female transgenic animals was 311 mg/dl, only -80 mg/dl higher than the mean level in the nontransgenic animals; nevertheless, the transgenic animals had more than a 10-fold increase in atherosclerotic lesion area as compared to the nontransgenic animals. What is the likely reason for this marked difference in susceptibility to atherosclerosis? The amount of cholesterol in the VLDL fraction does not appear to explain it, as little difference was observed in the amount of VLDL cholesterol in the transgenic mice and nontransgenic mice (Fig. 2) . However, the transgenic animals did have markedly increased amounts of cholesterol in the LDL fraction. In view of the abundant human and experimental animal data linking elevated LDL cholesterol levels to atherosclerosis (36), it is very difficult to avoid the conclusion that the increased amount of LDL cholesterol in the transgenic animals was the principal factor underlying the striking increase in atherosclerosis in those animals ( In addition to the increased amounts of LDL cholesterol in the transgenic animals, it is possible that the composition of the LDL was particularly atherogenic. In the chow-fed transgenic animals, the LDL was enriched in triglycerides (16) . On the high-fat diet, the LDL contained large amounts of cholesteryl esters, but only small amounts of triglycerides. Furthermore, the human apo-B100 on the high-fat diet tended to be in somewhat larger particles. These large, cholesteryl ester-enriched LDL were probably atherogenic; large, cholesterol ester-enriched LDL appear to be quite atherogenic in monkeys (2) .
A second factor that could have contributed to the atherosclerosis in the transgenic animals on the high-fat diet was decreased HDL cholesterol levels. Both the transgenic and nontransgenic animals had marked decreases in HDL cholesterol levels on the high-fat diet (a finding typical of C57BL/6 mice [20, 33 ] ), but the transgenic mice had significantly lower HDL cholesterol levels than the nontransgenic animals. Although the metabolism of HDL in the transgenic mice is not yet understood, it is quite possible that the low HDL cholesterol levels in the transgenic animals significantly contributed to their susceptibility to atherosclerosis.
Because the consumption of a high-fat diet causes elevated apo-B100 levels in primates (2) and humans (37, 38), we found it interesting that the high-fat diet did not result in elevated levels of human apo-B 100 in the transgenic mice. On the highfat diet, the total human apo-B levels increased by 44% in the female transgenic mice, but the increase was entirely explained by increased amounts of human apo-B48. The reason for the increased amounts of apo-B48 is not readily apparent, as we were unable to document a significantly increased level of hepatic apo-B mRNA editing on the high-fat diet. One possible explanation for the increased apo-B48 levels on the high-fat diet is that this diet increases the efficiency of secretion of newly synthesized apo-B48, but has little effect on the efficiency of apo-B100 secretion. Alternatively, it is possible that the highfat diet markedly retards apo-B48 clearance rates without changing the apo-B 100 clearance rate. Whatever the mechanism, it appears to apply to both mouse apo-B48 and human
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Purcell-Huynh et al. . . apo-B48, as we have documented that the amount of mouse apo-B48 also increased significantly on the high-fat diet. In a survey of plasma apo-B levels in various inbred strains of mice, Lusis et al. (4) found that a high-fat diet affects apo-B48 and apo-B100 levels differently in the different inbred strains. In C57BL/6 mice, apo-B48 levels increased on a high-fat diet; however, the increase in apo-B48 was not observed in some of the other inbred strains. Because of these findings, we consider it likely that certain aspects of the lipoprotein phenotype associated with the human apo-B transgene (e.g., relative levels of apo-B48 and apo-B 100 on different diets) would differ depending upon the genetic background of the mice used in the experiment. Although the mechanisms controlling the relative levels of apo-B48 and apo-B 100 are not fully understood, our experiments indicated that the human apo-B transgenic mice on the high-fat diet have roughly equal amounts of apo-B48 and apo-B100 in their LDL-sized lipoproteins. Based on reports of the phenotypes of genetically altered mice (10, [12] [13] [14] [15] , it is our opinion that both apo-B48-containing and apo-B100-containing lipoproteins are atherogenic. The results of this study do not permit us to dismiss the possibility that the high levels of LDL-apo-B48 on the high-fat diet are particularly important in contributing to the development of atherosclerosis. At present, we have no experimental data addressing the relative atherogenicities of the apo-B48-and apo-B100-containing lipoproteins. In the future, however, we do expect to be able to address this issue, using recently generated mice that synthesize exclusively apo-B48 (apo-B48-only mice) or exclusively apo-B100 (apo-B100-only mice) (Farese, R. V., Jr., and S. G. Young, unpublished observations).
In this study, the atherosclerotic lesions were rigorously quantified by computerized techniques. Images of each of the sections were obtained with a video camera attached to a light microscope; the images were stored on an optical disk, where they could be retrieved easily and reviewed for their accuracy. We believe that this computerized lesion quantification system greatly minimizes the subjectivity and technical errors that can occur when lesions are quantified manually, using a counting grid within the eyepiece on the microscope. In addition, it is noteworthy that we examined a considerably larger sample of sections per unit length than has been done in most previous studies of mouse atherosclerosis, where as few as four sections (per animal) have been analyzed (39, 40) . This thorough pathologic examination allowed us to document that the difference in the extent of lesions between transgenic and nontransgenic mice depends upon the distance of the sections. For example, whereas the transgenic females had sevenfold more lesions within the proximal 400 um of the aorta, they had 46-fold more lesions between 800 ,um and 1,200 ,utm from the aortic valve. In summary, we have shown that human apo-B transgenic mice develop high plasma levels of LDL cholesterol and severe atherosclerotic lesions in response to a high-fat diet. These findings occur in the hemizygous state, in contrast to findings in the LDL-receptor knockout or apo-E knockout mice, which must be bred to homozygosity to demonstrate the dramatic lipoprotein phenotype and the severe atherosclerotic lesions. While each of these mouse models is of obvious importance for future genetic and pathologic studies, the dominant phenotype of the human apo-B transgenic mice will undoubtedly prove useful for certain types of genetic studies. For example, in studies designed to identify the effects of other transgenes on atherogenesis in the mouse, or to identify new genes involved in atherogenesis, the use of an animal model with a dominant phenotype would reduce the number of matings required to set up an experiment and observe an effect.
